Human Papillomaviruses : Disease Burden in the United States
Anogenital HPV infection is believed to be the most common sexually
transmitted infection in the United States. An estimated 79 million persons
are infected, and an estimated 14 million new HPV infections occur annually
with half of these in persons 15-24 years.
The two most common types of cervical cancer worldwide, squamous cell
carcinoma followed by adenocarcinoma, are both caused by HPV. The CDC and
National Cancer Institute’s United States Cancer Statistics Working Group
reports that from 2005 through 2009 there were annual averages of 12,595
cases and 3,968 deaths due to cervical cancer. HPV is believed to be
responsible for nearly all of these cases of cervical cancer. HPV types 16
and 18 are associated with 70% of these cancers.
In addition to cervical cancer, HPV is believed to be responsible for 90%
of anal cancers, 71% of vulvar, vaginal, or penile cancers, and 72% of
oropharyngeal cancers.
Population-based estimates, primarily from clinics treating persons with
sexually transmitted infections, indicate that about 1% of the sexually
active adolescent and adult population in the United States have clinically
apparent genital warts. More than 90% of cases of anogenital warts are
associated with the low-risk HPV types 6 and 11.
About 8 billion dollars are spent annually on management of sequelae of HPV
infections, primarily for the management of abnormal cervical cytology and
treatment of cervical neoplasia. This exceeds the economic burden of any
other sexually transmitted infection except human immunodeficiency virus.
Prevention
HPV Infection
HPV transmission can be reduced but not eliminated with the use of physical
barriers such as condoms. Recent studies demonstrated a significant
reduction in HPV infection among young women after initiation of sexual
activity when their partners used condoms consistently and correctly.
Abstaining from sexual activity (i.e., refraining from any genital contact
with another individual) is the surest way to prevent genital HPV
infection. For those who choose to be sexually active, a monogamous
relationship with an uninfected partner is the strategy most likely to
prevent future genital HPV infections.
Cervical Cancer Screening
Most cases and deaths from cervical cancer can be prevented through
detection of precancerous changes within the cervix by cervical cytology
using the Pap test. Currently available Pap test screening can be done by a
conventional Pap or a liquid-based cytology. CDC does not issue
recommendations for cervical cancer screening, but various professional
groups have published recommendations. Cervical cancer screening
recommendations were revised in 2012 after the U.S. Preventive Services
Task Force (USPSTF) and a multidisciplinary group, including the American
Cancer Society (ASC), American Society for Colposcopy and Cervical
Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP)
reviewed new evidence. Previously, recommendations varied by organization.
Since 2012, all organizations have recommended that screening should begin
at age 21 years.
While there are slight differences in other aspects of the
recommendations, all groups recommend screening in women aged 21 to 65
years with cytology (Pap test) every 3 years. For women aged 30 to 65 years
who want to lengthen the screening interval, screening can be done with a
combination of cytology and HPV testing (“co-testing”) every 5 years.
The use of HPV vaccine does not eliminate the need for continued Pap test
screening, since 30% of cervical cancers are caused by HPV types not
included in the vaccine.
Tuesday, January 8, 2019
Human Papillomaviruses : Disease Burden in the United States
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment